TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04228913

Intervention type: OTHER
Group type: OTHER
Intervention: Root Canal Obturation Technique
Description: This study aims to compare the effects of three different obturation techniques(cold lateral condensation,thermoplasticized solid-core carrier method, cold free flow compaction technique) on postoperative pain following the endodontic therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Root Canal Obturation Technique
Description: This study aims to compare the effects of three different obturation techniques(cold lateral condensation,thermoplasticized solid-core carrier method, cold free flow compaction technique) on postoperative pain following the endodontic therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Root Canal Obturation Technique
Description: This study aims to compare the effects of three different obturation techniques(cold lateral condensation,thermoplasticized solid-core carrier method, cold free flow compaction technique) on postoperative pain following the endodontic therapy
Study: NCT03587324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole blood aggregometry before and after vascular treatment (ASA/ Clopidogrel).
Description: To identify possible risk factors demographic data, concomitant medication, laboratory parameters, co-morbidities, severity of the condition and the type of procedure performed are documented.~Other Name: ASA (aspirin), Clopidogrel (Plavix)
Study: NCT03906552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nonpharmalogocial methods
Description: neonates received acupressure (acupressure group) or massage (massage group) before heel lancing procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nonpharmalogocial methods
Description: neonates received acupressure (acupressure group) or massage (massage group) before heel lancing procedure
Study: NCT03909269

Intervention type: DEVICE
Intervention: Continuous glucose monitoring
Description: Continuous glucose monitoring five times over 17 weeks

Intervention type: DEVICE
Intervention: Continuous glucose monitoring
Description: Continuous glucose monitoring five times over 17 weeks

Intervention type: DIAGNOSTIC_TEST
Intervention: Glycaemic markers
Description: Measurement of HbA1c by immunoassay (Roche) and chromatography (TOSOH), including glycated albumin and fructosamine.

Intervention type: DIAGNOSTIC_TEST
Intervention: Glycaemic markers
Description: Measurement of HbA1c by immunoassay (Roche) and chromatography (TOSOH), including glycated albumin and fructosamine.

Intervention type: RADIATION
Intervention: Erythrocyte life span
Description: Erythrocyte life span measured by Crom-51 labelling over 4 weeks

Intervention type: RADIATION
Intervention: Erythrocyte life span
Description: Erythrocyte life span measured by Crom-51 labelling over 4 weeks

Intervention type: DEVICE
Intervention: Carbon monoxide (CO)-rebreathing method
Description: Measurement of total blood volume, plasma volume and erythrocyte volume
Study: NCT03452254

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Bihemispheric Transcranial direct current Stimulation
Description: The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Active tDCS: The anodic electrode will be put on affected M1. The cathodic electrode will be put on contralateral M1. We will apply a constant current of 2mA of intensity during 20 minutes while the patient performs the occupational therapy session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Bihemispheric Transcranial direct current Stimulation
Description: The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Sham tDCS: We will use the same place and parameters of stimulation applied for the active group, but the stimulator will deactivate after 30 seconds of stimulation. This will ensure that the patient will feel the initial tingling sensation at the beginning of the tDCS which is a requisite for blinding. The occupational therapy session will last one hour.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Modified Constraint Induced Movement Therapy
Description: Both groups will perform the mCIMT during a period of seven consecutive days. This protocol consists of two elements:~1. Restriction of the movements of the non-affected hand by wearing a mitt during six hours a day: we will use a mitt that limits the movement of the fingers but allows the free movements of the wrist, elbow, and shoulder.~2. Intensive and individualized training of the affected arm during 2 hours a day guided by an occupational therapist: the two hours training will be divided into two sessions of one hour each. Sessions will be organized in three blocks: preparation, activation, and function. In the third block, devoted to function, the patient has to choose one activity of daily living that he wants to improve.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Constraint Induced Movement Therapy
Description: Both groups will perform the mCIMT during a period of seven consecutive days. This protocol consists of two elements:~1. Restriction of the movements of the non-affected hand by wearing a mitt during six hours a day: we will use a mitt that limits the movement of the fingers but allows the free movements of the wrist, elbow, and shoulder.~2. Intensive and individualized training of the affected arm during 2 hours a day guided by an occupational therapist: the two hours training will be divided into two sessions of one hour each. Sessions will be organized in three blocks: preparation, activation, and function. In the third block, devoted to function, the patient has to choose one activity of daily living that he wants to improve.
Study: NCT02839395

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention- base line
Description: the subject will sited in a dim light room. No screen light illumination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute
Description: The subject will be sited in front of computer screen light illumination for 2 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronic
Description: The subject will be sited in front of computer screen light illumination for 2 hours for 5 consecutive days.
Study: NCT03363984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single oral administration of 2 mg midazolam under fasted conditions/outside of meal times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID-082
Description: Administration of ID-082 under fasted conditions/outside of meal times
Study: NCT01979276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin intravenously on days 1 and 15 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle
Study: NCT03367923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Receive email/text

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo exercise counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo exercise counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit tracker
Description: Wear Fitbit tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit tracker
Description: Wear Fitbit tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02136316

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT03367923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive phone call
Study: NCT03814382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture needle
Description: Acupuncture needle
Study: NCT02216968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase vegetable intake in pre-school children
Description: 6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase vegetable intake in pre-school children
Description: 6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children.
Study: NCT03907176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: 300 mg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1 g
Study: NCT01925118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Irradiated donor lymphocyte infusion
Study: NCT03718884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Cocktail
Description: Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally
Study: NCT00374127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana blunt
Description: Blunts were fabricated by cutting the bottom third off a Dutch Master® cigar, removing all of the cigar tobacco, and replacing it with all of the marijuana contained in a NIDA marijuana cigarette (ca. 800 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: marijuana cigarette
Description: Marijuana cigarettes were provided by the National Institute on Drug Abuse.
Study: NCT02729402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Testing
Description: We will use a battery of neurocognitive tests to assess cognitive function before and after surgery
Study: NCT01635244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic valve replacement
Description: Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic valve replacement
Description: Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic valve replacement
Description: Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).
Study: NCT04451486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB cells
Description: 1x10\*5 CD61-Lin- cells /0.25mL DPBS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB cells
Description: 1x10\*6 CD61-Lin- cells /0.25mL DPBS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB cells
Description: 1x10\*7 CD61-Lin- cells /0.25mL DPBS
Study: NCT01661725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group ACYW135 Meningococcal Polysaccharide Vaccine
Description: 60 subjects were divided into three groups (20 subjects each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
Study: NCT03189563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-9805 45mg
Description: DA-9805 15mg tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-9805 90mg
Description: DA-9805 30mg tid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, tid
Study: NCT02640989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent influenza vaccine, Anflu®
Description: Seasonal trivalent influenza vaccine manufactured by Sinovac Co., Ltd.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent influenza vaccine, VAXIGRIP
Description: Seasonal trivalent influenza vaccine manufactured by PasteurSanofi Pasteur

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal trivalent influenza vaccine, Fluarix
Description: Seasonal trivalent influenza vaccine manufactured by GlaxoSmithKline Biologicals
Study: NCT03894267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutimed Siltec Heel and Sacrum dressing
Description: The dressing has been developed to facilitate exudate management in the treatment of wounds. Newly formed tissue enjoys optimal protection under a moist environment. The foam core with super-absorbers ensures reliable absorption in slightly to heavily exuding wounds. This core has an excellent retention capacity, even under compression. Hydrogen bridges bind the water so securely that, even when subject to pressure, the water is not released. Vertical absorption through the polyurethane foam and the hydro- phobic wound contact layer minimizes the risk of macerations in the peri-ulcer skin.
Study: NCT03208504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexus™ Aortic Arch Stent graft
Description: surgical implantation of Nexus™ Aortic Arch Stent graft
Study: NCT03734133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot insoles
Description: Different foot insoles of different hardness
Study: NCT02572089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Study: NCT03718884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Cocktail
Description: Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC
Study: NCT04574765

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: Nasopharyngeal swab for COVID-19

Intervention type: OTHER
Intervention: Questionnaire collection
Description: Fill out questionnaires regarding exposures and travel history, occupation category, any symptoms in the past 21 days, any face-to-face care of a known COVID-19 positive patients in past 14 days or any children at home who are less than 12 years of age.

Intervention type: OTHER
Intervention: Optional blood completion
Description: Provide blood samples to look for COVID-19 specific antibodies and/or proteins at the time of enrollment and after 8 weeks.

Intervention type: OTHER
Intervention: Optional questionnaire completion
Description: Fill out an optional mental health questionnaire.
Study: NCT02591589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normoxic oxygenation
Description: FiO2 set at 0.35 to maintain PaO2 \> 70 mmHg or oxygen saturation greater than or equal to 92%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperoxic oxygenation
Description: FiO2 set at 1.0 throughout the procedure
Study: NCT04679675

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects will receive Kaiser Permanente Washington standard of care.
Study: NCT00958347

Intervention type: DEVICE
Group type: OTHER
Intervention: Omnifit HA Hip Stem
Description: Total Hip Replacement with Omnifit HA Hip Stem
Study: NCT00990431

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional carbon dioxide laser treatment
Description: The CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA) employs disposable tips with a diameter of 7 mm and 15 mm, the smaller being used for the peri-orbital region. The laser beam is delivered through multiple deflective and refractive elements and focused to a spot size of approximately 120 µm in diameter at incidence to the skin to deposit an array of laser beams across the surface. Pulse energy varies from 5 to 70 mJ and density from 5 to 70 %. The pulse duration is 10 msec. In the present study, patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional erbium:YAG laser treatment
Description: The Er:YAG laser used in this study has a fractional handpiece (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany). By means of a microlens array the laser beam is divided into 13 x 13 small spots with 250 µm diameter each, spread over an area of 13 x 13 mm. A coverage of 5 % of the skin is achieved with a single pass. The pulse duration is 400 μsec. In this trial, we performed 4 passes (resulting in coverage of 20 % of the treated skin) with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses) to optimize thermal exposure.
Study: NCT01214408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered pantoprazole
Description: Buffered pantoprazole 40 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered pantoprazole
Description: Buffered pantoprazole 40 mg QD
Study: NCT03783442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil (5-FU)
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered orally
Study: NCT04679675

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening.
Study: NCT02551328

Intervention type: DRUG
Intervention: sevofluorane
Description: Continuous infusion of sevofluorane
Study: NCT04679675

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Direct Mail
Description: Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will also receive an insert describing the home-based cervical cancer screening option and that a kit will be sent within 1 week. An HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opt-in
Description: Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will receive an Opt-in Insert describing the home-based cervical cancer screening option and how to request a kit. Individuals can request a kit by phone or through a webpage. Individuals who request a kit will receive the HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
Study: NCT03680638

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control (Lactated Ringer's)
Description: This intervention is meant to serve as a control by which the experimental sites are compared to, to assess effectiveness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tempol
Description: This intervention is meant to assess the impact of superoxide on vasodilator responses by scavenging available superoxide.
Study: NCT03806140

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: text messages
Description: receive about one health-related text message a day for 16 weeks